CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for brain lymphoma: acalabrutinib trial underway
Disease control OngoingThis phase 1/2 trial tests the drug acalabrutinib (Calquence) in 49 people with central nervous system lymphoma that has come back or not responded to treatment. Participants take the tablet by mouth twice daily. The study aims to find the safest dose and see if the drug can shri…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising drug may shrink brain tumors in relapsed lymphoma
Disease control OngoingThis study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and w…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immune cells take on brain cancer in first human test
Disease control OngoingThis early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Hrain Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo takes aim at brain lymphoma
Disease control OngoingThis phase 2 trial tests a combination of six drugs (TEDDI-R) in 48 adults with aggressive B-cell lymphoma that has spread to the central nervous system. The goal is to see if this mix can control the cancer better than current treatments. Participants receive the drugs in 21-day…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can a 'Clean-Up' drug make chemo safer for brain lymphoma?
Disease control OngoingThis early-phase trial tests whether adding glucarpidase (Voraxaze) to standard methotrexate and rituximab can safely lower methotrexate levels in the blood for people with central nervous system lymphoma. About 58 participants will receive different doses of methotrexate along w…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Matched conditions: CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC